Walleye Trading
NRXP icon

Walleye Trading’s NRX Pharmaceuticals NRXP Stock Holding History

Walleye Trading’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-30
Closed -$3K – 5087
2018
Q3 		$3K Buy
+30
New +$2.98K ﹤0.01% 5167

Other funds holding NRXP

HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

Walleye Trading's NRXP Position: Q4 2018 in Review

Walleye Trading sold out of NRX Pharmaceuticals (NRXP) in Q4 2018, closing a stake of 30 shares — an estimated $3K sold.

Walleye Trading first reported a position in NRXP in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 20 funds tracked by Wall St. Rank hold NRXP as of Q4 2018.

  • Walleye Trading reported no remaining NRX Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Walleye Trading sold 30 NRX Pharmaceuticals shares in Q4 2018, an estimated $3K.
  • Walleye Trading first reported a position in NRX Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Walleye Trading's NRX Pharmaceuticals position peaked at $3K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2018.

Based on Walleye Trading's 13F filing for Q4 2018, filed 14 Feb 2019.